Sun Pharma Q4 FY26 Results

Consolidated Sales: ₹14,559.8 crore
Reported Net Profit: ₹2,714 crore

Reader Takeaway: Strong growth in innovative medicines and India business offset US generic pressures; FY27 outlook is positive.

What just happened

Sun Pharmaceutical Industries Limited announced its financial results for the fourth quarter and full year of fiscal year 2026. The company reported consolidated sales of ₹14,559.8 crore for Q4 FY26, a 13.6% year-on-year increase. Net profit for the quarter stood at ₹2,714 crore. For the full fiscal year FY26, consolidated sales reached ₹58,200 crore. The Board of Directors approved a total dividend of ₹16 per share for FY26, comprising a final dividend of ₹5 and an interim dividend of ₹11.

Why this matters

The results indicate Sun Pharma's continued growth, particularly driven by its innovative medicines segment and a strong performance in the Indian market. The declared dividend provides a direct return to shareholders. The guidance for high single-digit consolidated top-line growth in FY27 suggests confidence in future performance, although pressures in the generic business and evolving margins require attention.

The backstory

Sun Pharma has been focusing on strengthening its specialty and innovative medicine portfolio while navigating the competitive landscape of the US generic drug market. The company has also been investing in expanding its manufacturing capabilities and product pipeline, including recent launches like a semaglutide injection and UNLOXCYT for cancer treatment.

What changes now

With the Q4 results and FY27 guidance, investors have a clearer picture of the company's performance trajectory. The approved dividend will be distributed to shareholders. The strategic focus on innovation and expansion is expected to continue influencing the company's financial performance in the upcoming fiscal year.

Risks to watch

Potential risks include intensified competition in the US generic market, pricing pressures, and regulatory compliance issues at manufacturing sites which could affect new approvals. Elevated operating expenses due to new product launches and geographical expansion also need to be monitored, impacting margin trends.

Peer comparison

Sun Pharma's India business growth of 14.8% in Q4 FY26 outpaced the market, showcasing strength against domestic peers. The US business saw a marginal decline due to competition, a common challenge faced by many Indian pharmaceutical companies operating in that market. The company's EBITDA margin of 27.1% for the quarter was lower sequentially, which investors will compare with global and domestic pharmaceutical players.

Context metrics (time-bound)

• Q4 FY26 Sales: ₹14,559.8 crore (up 13.6% YoY)
• Q4 FY26 Net Profit: ₹2,714 crore
• Q4 FY26 EBITDA Margin: 27.1%
• FY26 Full Year Sales: ₹58,200 crore
• FY26 Dividend: ₹16 per share
• FY27 Guidance: High single-digit consolidated top-line growth

What to track next

Investors will be watching the integration of the Organon acquisition, the performance and market uptake of new specialty products like UNLOXCYT, the impact of ongoing generic competition, and the normalization of operating margins in the coming quarters. The company's ability to manage its operating expenses while driving innovation will be crucial.